The PUWMa (Pfizer-funded study from the University of California Los Angeles (UCLA), Washington University (WASH-U), and Massachusetts General Hospital (MGH)) GWAS of ADHD

The PUWMa GWAS of ADHD is a multi-site collaboration initiated to conduct a family-based association study from existing research samples. The source sample of ADHD families was ascertained at Massachusetts General Hospital (MGH, N=309 trios), Washington University at St. Louis (WASH-U, N=272 trios), and University of California at Los Angeles (UCLA, N=156 trios). All offspring met criteria for DSM-IV-TR attention-deficit hyperactivity disorder with childhood onset.

• Study Design:
  • Family/Twin/Trios
• Study Type:
  • Parent-Offspring Trios
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 1383
• Subject Sample Telemetry Report (SSTR)

At MGH, initial affection status was based on DSM-IIIR criteria but lifetime DSM-IV-TR criteria was confirmed with Schedule for Affective Disorders and Schizophrenia for School-Age Children Epidemiologic Version (K-SADSE) at follow-up assessments. At UCLA, children and adolescents were assessed using the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL). At WASH-U subjects were assessed with the Missouri Assessment of Genetics Interview for Children (MAGIC), a semi-structured psychiatric interview allowing DSM-III, DSM-IV, and ICD-10 diagnoses. Cases were excluded if they were positive for any of the following: neurological disorder, head injury resulting in concussion, lifetime diagnoses of schizophrenia or autism. With regard to cognitive ability, MGH and UCLA subjects with estimated Full Scale IQ was <80 or <70, respectively were excluded while subjects at WASH-U were excluded if parents reported mental retardation.

• Primary Phenotype: Attention Deficit Hyperactivity Disorder

• Co-Principal Investigators
  • Stephen V. Faraone, PhD. Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.
  • Eric Mick, ScD. Departments of Psychiatry at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Susan Smalley, PhD. UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA, USA.
  • Alexandre Todorov, PhD. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
• Co-Investigators
  • Joseph Biederman, MD. Departments of Psychiatry at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Alysa Doyle, PhD. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
  • Timothy Wilens, MD. Departments of Psychiatry at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Janet Wozniak, MD. Departments of Psychiatry at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Benjamin M. Neale, PhD. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
  • Sandra Loo, PhD. UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA, USA.
  • James McCracken, MD. UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA, USA.
  • James McGough, MD. UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA, USA.
  • Stanley F. Nelson, MD. UCLA Department of Human Genetics, Los Angeles, CA, USA.
  • Angela M. Reiersen, MD. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
• Funding Source for Genotyping
  • Pfizer, Inc., New York, NY, USA.
• Funding Source for Sample Acquisition
  • U01MH085518. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • R13MH059126. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • R01MH62873. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • R01MH081803. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • R01NS054124. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
  • K23MH001966. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • K24DA016264. National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
  • R01MH058277. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • R01MH066237. National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.